Astrazeneca Pharma India Limited · NSE:ASTRAZEN

Astrazeneca Pharma India — Shareholder Meeting (2025)

31 slides from Astrazeneca Pharma India's shareholder meeting presentation, 2025

  1. Slide 1: 46th AGM 2025 Corporate Presentation

    012345672684ÿ 43 4ÿ74ÿ 26 07 7 4ÿ67 634 ÿ6 62 ÿ ÿ!""#$%%& 7 '(#(ÿ)#*+ÿ ,-./ÿ12324.ÿ5657

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation by AstraZeneca Pharma India Limited (the “Company”) is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner. This present

  3. Slide 3: [= EÿB "CB" 

    01234567684ÿ7 4ÿ 126ÿ722ÿ43 [=EÿB"CB" ÿÿÿ!" ÿ<B?ÿ>= ÿ=;CÿDE; #$%&'()'*+,ÿ.ÿ/+,0 /+,012)345&6)ÿ7,8)(),8),5ÿ /+,012)345&6)ÿ7,8)(),8),5ÿ 12)345&6)ÿ7,8)(),8),5ÿ 9&')35+' 9&')35+' 9&')35+' ÿ?ÿF ÿZ==ÿ[;ÿ\"ÿ ÿ˜"ÿ™š<== /+,012)345&6)ÿ9&')35+'Gÿ /+,012)345&6)ÿ9&')35+'Gÿ /+,012)345&6)ÿ9&')35+' HIJKLMNOPLQRSÿUL

  4. Slide 4: 8ÿ ÿ 012345 ÿ ! 8ÿ 7ÿ"8ÿ9ÿ#9$

    6 789 8ÿ 6 ÿ 6 989 012345 6 9 8 6 ÿ 6 ! 8ÿ 6 7ÿ"8ÿ9ÿ#9$

  5. Slide 5: 012341ÿ67849

    012341ÿ67849

  6. Slide 6: Our 2030 Bold Ambition

    OUR 2030 BOLD AMBITION Our bold aspiration is to be pioneers in science, lead in our disease areas, and transform patient outcomes By 2030, we will deliver 20 new medicines, be a $80bn company and be carbon negative GLOBAL STRATEGIC PRIORITIES It starts with advancing the right science and technolog

  7. Slide 7: Ambition — $80bn Total Revenue by 2030 & sustained 2030+ growth

    5 Ambition — $80bn Total Revenue by 2030 & sustained 2030+ growth Working on “today, tomorrow and the day after" Illustrative only, not to scale Launching key NMEs AZD0120 saruparib AZD0486 volrustomig se = camizestrant AZN ADCs Existing portfolio rilvegostomig Calquence Imfinzi/imjudo baxdrostat IV

  8. Slide 8: H1 2025 — growth supported by diverse, broad-based business

    H1 2025 — growth supported by diverse, broad-based business H1 2025 | % Total Revenue by therapy area 16% 10% Rl: 4 18% 13% Oncology CVRM R&l V&l Other Rare Disease Strength across 43% 23% 15% 1% 2% 15% therapy areas 3% | | rams Nseries “ 11,955 4,336 Oncology BioPharmaceuticals Rare Disease H1 2025

  9. Slide 9: India Update

    India Update Praveen Rao Akkinepally MANAGING DIRECTOR

  10. Slide 10:  56ÿ89:;<9ÿ=>?@A5ÿ ÿB"C$DE  F59G<H?965ÿ0ÿI.0.2ÿIJKL2M.NÿO+P(0ÿ 3Q2+P3ÿRSTUÿ@Vÿÿ*+ÿWXNÿQ)0+ÿ.*ÿ

    0123456ÿ8951ÿ 131 ÿ3513 34 ÿ ÿ"#$%ÿ&'())(*+ÿ,-./ÿ)0'123.4 56ÿ89:;<9ÿ=>?@A5ÿÿB"C$DE F59G<H?965ÿ0ÿI.0.2ÿIJKL2M.NÿO+P(0ÿ ”•–—˜™šÿœ–žŸšÿ¡Ÿ¢•£–£¤ 3Q2+P3ÿRSTUÿ@Vÿÿ*+ÿWXNÿQ)0+ÿ.*ÿ ¥RS¦§ÿ̈>ÿ@:©G9<;@> YZ[\]ÿ_àbÿcdÿe_a §ªÿ«<9<5¬ fghijkÿljghjÿmkg n*o.$ÿp*'ÿ)03.ÿqqÿr20'3ÿ,#'Pÿ.2's4 t*MJ3ÿ*+ÿu9v5ÿ;>ÿ=>w;9ÿx ;

  11. Slide 11: 012ÿ4124567ÿ86ÿ 95167ÿ251 ÿ 748ÿ527ÿ 4876ÿ87ÿ 772ÿ7872ÿ 876ÿ

    012ÿ4124567ÿ86ÿ 95167ÿ251 ÿ 748ÿ527ÿ 4876ÿ87ÿ 772ÿ7872ÿ 876ÿ

  12. Slide 12: gh'?W0&FW V#0%?&W?Z&$&%( E?N%W/N0P&'0ÿ E/F'$/

    01234ÿ678479 ÿ36ÿ43192ÿ37ÿ4ÿ83837396ÿ412ÿ 894316ÿ16367917ÿ ÿÿÿÿ !"#$%&'$(!ÿ)*+ÿÿ+), j c d m e f gh'?W0&FW -../00 =& > &%? $ E?N%W/N0P&'0ÿ E/F'$/ V#0%?&W?Z&$&%( 1;:4H;4ÿ6ÿ1i4;:39:L2 12324ÿ6ÿ789:;< @)A,),ÿBÿC,*)D) kHH8J32:8Hÿ6ÿlI G394H2ÿ6ÿI:J4KL:2< [4K8ÿ\3K]8Hÿ6ÿ^_`:2< MN -N/F?O% ÿT/P?ÿRÿ U/SNP0/PN&'?

  13. Slide 13: 079;<=ÿ>;??39>@12:39A;9?1<>31<BÿA@<1<>@12ÿ 3C3>D7@;<ÿ@<ÿEFÿGHGIJGK E@<1<>@12ÿ4<1:48;7ÿ;AÿEFÿGHGIJGK U

    01234ÿ67897 ÿ ÿ687699ÿ 079;<=ÿ>;??39>@12:39A;9?1<>31<BÿA@<1<>@12ÿ 3C3>D7@;<ÿ@<ÿEFÿGHGIJGK .ÿ01234ÿ56ÿ78391:6ÿ1931 L;712ÿM3N3<D3OPQM@<ÿ?<R STG. V-WX + EFÿGHGTJGI EFÿGHGIJGK E@<1<>@12ÿ4<1:48;7ÿ;AÿEFÿGHGIJGKU ÿÿ!""#$ÿ%&'ÿ()ÿ*+*,*-

  14. Slide 14: <=>?@ABCBD@ÿF=ÿ@GHCI=>ÿ>JBÿK@=>B=>ÿI?HLFCIÿDHGM@CFB=ÿFCÿ NCOF@CÿPJ@?G@DBQ>FD@RÿS@?TB>

    <=>?@ABCBD@ÿF=ÿ@GHCI=>ÿ>JBÿK@=>B=>ÿI?HLFCIÿDHGM@CFB=ÿFCÿ NCOF@CÿPJ@?G@DBQ>FD@RÿS@?TB> —_\{}ÿš|~ÿ_zV\]}|ÿ›U˜}ÿtpÿœ‚‹ x ”\^VZV]ÿb[}\`}}ÿa_\{}ÿ\ctpÿœ‚ •a}|ÿ”\^VZV]ÿba_\cÿ UVWXÿZ[\]ÿ^_\^`aÿ yvmnjtpmÿtnmÿz_a{`|ÿ ‰jvpqulhÿtpÿŒ€aZÿŽXÿtmÿ’“jmnlmnÿkgrˆtpkÿj†rpkÿ |Vÿ}[a€_}}ÿ–U—ÿŽŽÿ˜aÿ ba_\cÿdÿfghÿ

  15. Slide 15: !"#$%#$%ÿ#$$'()*#(+ÿ,+-#.#$+/ÿ*'ÿ0$-#)ÿ#$ÿ12ÿ34536ÿ 012ÿ415676819ÿ85ÿ55668ÿ68567689 0 012ÿ415676819ÿÿ ÿ1ÿ8715

    !"#$%#$%ÿ#$$'()*#(+ÿ,+-#.#$+/ÿ*'ÿ0$-#)ÿ#$ÿ12ÿ34536ÿ 012ÿ415676819ÿ85ÿ55668ÿ68567689 0 012ÿ415676819ÿÿ ÿ1ÿ8715

  16. Slide 16: !"#$%&'$&(ÿ"*ÿZ,%&,(,[, 2;;@;6467ÿ@93=6;3<?4@ÿ=Aÿ ;6?96:;ÿ9::;<<ÿ96Wÿ?;9B=?:93;ÿ

    012345647ÿ93 76ÿ33649ÿÿ 3ÿ ÿÿ !"#$%&'$&(ÿ"*ÿZ,%&,(,[, !"#$%&'$&(ÿ"*ÿ!", !"#$%&'$&(ÿ"*ÿ+,'-.ÿ/,01 2;;@;6467ÿ@93=6;3<?4@ÿ=Aÿ EFGHIJKÿMHNKOÿKOIOPÿOQÿHFOPRNIOPÿ 2345467ÿ9::;<<ÿ464=49=45;<ÿ>ÿ ;6?96:;ÿ9::;<<ÿ96Wÿ?;9B=?:93;ÿ ;93BCÿ<:3;;6467SÿTUVÿW9=9ÿ>ÿ <?9@467ÿ@AB4:Cÿ@34A34=4;<D 466A59=4A6 :A6X4W;6=49Bÿ@3

  17. Slide 17: ()ÿ(++,-,./01.ÿ2345367ÿ C<D34B?@E<5ÿFG(Hÿ1IÿJKÿ 9763D:3cÿd6;D:3cÿe:DD:3fÿ 9:6;4<ÿ=ÿ>6?<@A:B 0,/FLÿM6ÿB6E>Nÿ

    0123456ÿ83ÿ98ÿ4641ÿ131444ÿ9ÿ159ÿ ÿ!ÿ"#$#%ÿ&#' ()ÿ(++,-,./01.ÿ2345367ÿ C<D34B?@E<5ÿFG(Hÿ1IÿJKÿ 9763D:3cÿd6;D:3cÿe:DD:3fÿ COÿPE3;Dÿ763Q:DÿD4ÿ?;:ÿ 9:6;4<ÿ=ÿ>6?<@A:B 0,/FLÿM6ÿB6E>Nÿ (H ÿag/0hb i RSTUVWXÿZ[T\U]^[]ÿ_[Vÿ @4726<E4< `abÿ+/--L

  18. Slide 18: DEFGHIJÿLMGÿNMGNLOPÿQLIOHORPIRSTÿHIÿREPÿQLMIRGT

    DEFGHIJÿLMGÿNMGNLOPÿQLIOHORPIRSTÿHIÿREPÿQLMIRGT 6 ÿ!,781-0ÿ 9:1,00,;1,ÿ-<-+7ÿ=>ÿ //? 012ÿ456789 ÿÿÿÿ ÿÿ ! "#$ÿ%&'#()ÿ*+,-.ÿ /0-1,ÿ23ÿ43+5ÿ '#(('#( @A;;,+ÿABÿCÿ(ÿ ÿ'#ÿ=>ÿ//?

  19. Slide 19: 0123456ÿ83249ÿ2ÿ432ÿ53292 ÿ !ÿ#

    0123456ÿ83249ÿ2ÿ432ÿ53292 ÿ !ÿ#

  20. Slide 20: DEFGFÿIJKÿLMNOÿPQRÿSTÿÿUVÿMNOÿ PQRÿSWX G RG†GI‡ÿONÿEQJˆGJMN RQÿLM‰X

    ÿ!"#$%&##ÿ'(%)$%"&#ÿ*(!"#)ÿ+*(,)-ÿ opqrsÿuvÿwxyz #"..(*)&/ÿ!0ÿ1%%(23)$2&ÿ4'$&%'& DEFGFÿIJKÿLMNOÿPQRÿSTÿÿUVÿMNOÿ G RG†GI‡ÿONÿEQJˆGJMN RQÿLM‰X ŠQ‡ÿ‹JN PÿEQJˆGJMN RQ PQRÿSWX IJK 012 lm300 WWK ThK ~~|~{~ÿ 552 542 {|}~~ÿ SihkTÿ TnK 342 SijWWÿ jkfK 67 89 1ÿ 91ÿ8 €€‚ƒ€„ €€„ƒ€} 56ÿ89:;ÿ<5=ÿ>?@ABC 3 fghÿnK

  21. Slide 21: :><75?@5A?6?7;ÿBÿC4<?6?4@94ÿ D$EFFGHIÿJKLMNOÿQROSÿTÿUVÿ RWXYZKW[KN\ÿRW[YZ]RW^ÿ_M`abcÿ

    012314516ÿ28392438ÿ84 8ÿ4993 3589ÿ51ÿ 1496ÿ31ÿ58ÿ9368ÿ4398ÿ3581ÿ33818 ÿ!"ÿ#$%&'()&*+,-ÿ kSKÿRWRORhORlKÿSKYLRW^ÿOMÿ u517@41<8?oÿv?78ÿwxyyxÿ3456ÿOMÿ /01ÿ3456789514ÿ:;<74=<ÿ 4<75A6?<8ÿmn:ÿo657/01=pA5<4qÿ gZRY]ÿLNM^NK\\RlKÿh[[K\\ÿ :><75?@5A?6?7;ÿBÿC4<?6?4@94ÿ 6>@rÿ95@941ÿA?0=51s41ÿ74<7?@rÿ \ONhOK^RK\ÿRW

  22. Slide 22: CCDÿEFÿG<@HI@J:AK<ÿLMAN 7ÿ9:;<=ÿ>?ÿ>@:AB= CCDÿOI@PHI;QIÿR@<Sÿ>?ÿT7ÿB<=OQP<ÿIHÿU<:BSQAB=ÿH@IJÿR<A<@QKÿ>@:AB=ÿ

    01234567589 185 ÿÿÿÿÿ ÿÿÿÿ ÿ CCDÿEFÿG<@HI@J:AK<ÿLMAN 7ÿ9:;<=ÿ>?ÿ>@:AB= T7 CCDÿOI@PHI;QIÿR@<Sÿ>?ÿT7ÿB<=OQP<ÿIHÿU<:BSQAB=ÿH@IJÿR<A<@QKÿ>@:AB=ÿ !"#$%&'ÿ)**#+,ÿ-&."$/ÿ01ÿ2324526

  23. Slide 23: ?-("@-4*A+-.ÿ.)*&4$6)6Bÿ%6)4&ÿCDE FGHIHÿJÿHKHLÿÿMENLHÿ MOIPL

    012345617839ÿ 1638ÿ21ÿ169ÿ283ÿ 3188 ÿÿ!"#$%&"ÿ ?-("@-4*A+-.ÿ.)*&4$6)6Bÿ%6)4&ÿCDE ])!"ÿ!"-ÿ4*!)$4*+ÿ*:-#*&-ÿ$Zÿ '$()*+ÿ,-.)* FGHIHÿJÿHKHLÿÿMENLHÿ .)*&4$6-.ÿ6-:-#-ÿ*6!",*ÿ(*6-6Bÿ$%#ÿ /0112ÿ3*!)-4!ÿ-.%(*!)$4ÿ5$6!6 MOIPL ^IHLÿMLÿ*#-ÿA#).&)4&ÿ!"-ÿ&*5_ /78ÿ9):-ÿ6-66)$46ÿ;)!"ÿ-<5-#!6 /Q0ÿR*#.)*(ÿS%A6ÿ($44-

  24. Slide 24: 789:ÿ<=>:8>:ÿ8?89:@:>>ÿ:AB78C:ÿDE9ÿFGÿ H8IJÿDE9ÿ789:ÿ:K:@L> MEI=CNÿ<=>CO>>=E@>ÿ8LÿPQÿRE@:ÿSE>T=L8IGÿ

    !"#$ÿ&#"'(")ÿ!*$ÿ+# (,!" ÿ+-ÿ#-ÿ ./01ÿ3451/51ÿ6-!+'"ÿ ÿÿÿ 62 3415 789:ÿ<=>:8>:ÿ8?89:@:>>ÿ:AB78C:ÿDE9ÿFGÿ 012 H8IJÿDE9ÿ789:ÿ:K:@L> 676386769 67698676 MEI=CNÿ<=>CO>>=E@>ÿ8LÿPQÿRE@:ÿSE>T=L8IGÿ 9:A89<=@Aÿ8CC:>>ÿLEÿUVWÿ8@<ÿ8SXYÿ

  25. Slide 25: -./01231425206ÿ89:;9<=>ÿ;9ÿ?89:;@<A<B;ÿ 012ÿ24ÿ51ÿ6789488ÿ 12ÿ24ÿ$%&4ÿ%ÿ'189(9)4ÿ9$'%*( ÿÿÿÿÿÿ +""ÿ"ÿ# ÿ,ÿÿÿ!ÿ ÿÿÿÿÿÿ…

    -./01231425206ÿ89:;9<=>ÿ;9ÿ?89:;@<A<B;ÿ 012ÿ24ÿ51ÿ6789488ÿ 012ÿ24ÿ$%&4ÿ%ÿ'189(9)4ÿ9$'%*( ÿÿÿÿÿÿ +""ÿ"ÿ# ÿ,ÿÿÿ!ÿ ÿÿÿÿÿÿ ÿ!ÿ # ÿÿÿÿ""ÿ,ÿ ÿÿÿÿÿ!ÿ ,ÿ!ÿÿÿ"ÿ "ÿÿ#"ÿÿ ÿÿÿÿÿÿ

  26. Slide 26: „%%&$$ÿ*ÿw&-*x%"& 1,ÿw&-*xÿy""((& )ÿ#('%*+,-ÿ.&"$ÿ+ÿ&"-.ÿ%%&"ÿ &*&%*#ÿ z('"!#ÿ-{*&"(ÿx&-*xÿ…

    012ÿ4567589ÿ ÿÿÿ „%%&$$ÿ*ÿw&-*x%"& !#"(&*-ÿ,$*#|#-#*.ÿ ÿ !"#ÿ$%"&&#ÿ'""((& 1,ÿw&-*xÿy""((& y„ zÿ/y"!##ÿ†ÿ„,(&*#ÿ*,"-{ )ÿ#('%*+,-ÿ.&"$ÿ+ÿ&"-.ÿ%%&"ÿ&*&%*#ÿ z('"!#ÿ-{*&"(ÿx&-*xÿ,*%(&$ÿ+"ÿ "&$,"%&{|$&ÿz*&"!&*#$6 /01ÿ232452)6 !,-&"|-&ÿ-&$%&*$ ‡&!#!#ÿˆ*&"‰ÿ‡&$*"#ÿŠ#!&-#x$ 7 89:;<9=ÿ?@=9AB9AC9=ÿDEF9@ÿGHI

  27. Slide 27: IB@>ABCDÿPbDJ>ÿJbAc>d f 7&*)(8%1%9(ÿ+&ÿ(ÿV)%(*ÿW"(9%ÿ 7&*)(8%1%9(ÿ% :)(9%&ÿ/#1%&*$ÿ #0)ÿ&0&*(+1(:+"+*$ÿ!)+#)+*+%&ÿ

    012ÿ4567ÿ9 ÿÿÿÿÿ IB@>ABCDÿPbDJ>ÿJbAc>d 3 4 5 !"#$%%&ÿ()%ÿ&(*+&,+%-ÿ.+*/ÿ 3 ; 5 !"#$%%&ÿ:%"+%2%ÿ < f 5 < = 5 !"#$%%&ÿ(6)%%ÿ*/(*ÿ !"#$%%&ÿ()%ÿ("+61%-ÿ.+*/ÿ #0)ÿ*("%1*ÿ-%2%"#! %1*ÿ 7&*)(8%1%9(ÿ+&ÿ(ÿV)%(*ÿW"(9%ÿ 7&*)(8%1%9(ÿ% :)(9%&ÿ/#1%&*$ÿ #0)ÿ&0&*(+1(:+"+*$ÿ!)+#)+*+%&ÿ +1+*+(*+2%& *#ÿY#)e (1-ÿ+1*%6)+

  28. Slide 28:  ÿ"#$%&%'$(ÿ*+,+'-ÿ./(*+0/1ÿ23ÿ$45"'"#&ÿ6+%#&ÿ.+0/#ÿ7 89ÿ:;<= >=ÿ;?>@;@@=>Aÿ =7B=C@;?Dÿ8 ÿC899;@9=?@ÿ@8ÿD=?:= ÿ:;…

    01234ÿ64ÿ78937ÿ643476ÿ 182ÿÿ763ÿ 843ÿ633 ÿ"#$%&%'$(ÿ*+,+'-ÿ./(*+0/1ÿ23ÿ$45"'"#&ÿ6+%#&ÿ.+0/#ÿ789ÿ:;<=>=ÿ;?>@;@@=>Aÿ =7B=C@;?Dÿ8ÿC899;@9=?@ÿ@8ÿD=?:=ÿ:;<=>;@EÿF?:ÿ;?CB>;8?ÿ;?ÿ>C;=?C=

  29. Slide 29: ÿ"#ÿ$%ÿ%$ÿ& ÿ '()*+,-ÿ/+01+ÿ21(3,4516738ÿ 9:ÿ;%9%ÿ$;ÿ:&<9:=&ÿ"#ÿ %<$=>?ÿ9:ÿ$@ÿ$;ÿ @:&9ÿ==ÿ=&ÿ$ÿAÿ ;$ÿ$<Bÿ$=9#ÿ& ÿ9:ÿ …

    ÿ"#ÿ$%ÿ%$ÿ& ÿ '()*+,-ÿ/+01+ÿ21(3,4516738ÿ 9:ÿ;%9%ÿ$;ÿ:&<9:=&ÿ"#ÿ %<$=>?ÿ9:ÿ$@ÿ$;ÿ @:&9ÿ==ÿ=&ÿ$ÿAÿ ;$ÿ$<Bÿ$=9#ÿ& ÿ9:ÿ <&9C 01ÿ 51ÿ7181 01ÿ345 36571859ÿ795 01ÿ36 5ÿ078 01ÿ ÿ51 75ÿ78 01ÿ61ÿ 851181476

  30. Slide 30: 0123456789ÿ2ÿ ÿ7ÿ 23ÿÿ5ÿ 62ÿÿ ÿ712ÿ 25523ÿ6256723ÿ 712ÿ

    0123456789ÿ2ÿ ÿ7ÿ 2 23ÿÿ5ÿ 62ÿÿ ÿ712ÿ 25523ÿ6256723ÿ 712ÿ

  31. Slide 31: 01234ÿ678ÿ 97ÿ678ÿ 73ÿ23ÿ ÿ7ÿ78ÿ 1ÿ76

    01234ÿ678ÿ 97ÿ678ÿ 73 8 73ÿ23ÿ 87 ÿ7ÿ78ÿ 7 1ÿ76

AstraZeneca Pharma India — Shareholder Meeting (2025) on 6ix